The protective potential of alpha lipoic acid on amiodarone-induced pulmonary fibrosis and hepatic injury in rats.
Ghadha I FouadMohamed R MousaPublished in: Molecular and cellular biochemistry (2021)
Amiodarone (AMD) is a widely used antiarrhythmic drug prescribed to treat cardiac tachyarrhythmias; however, AMD has been reported to provoke pulmonary fibrosis (PF) and hepatotoxicity. This study aimed to investigate the influence of alpha lipoic acid (ALA) on AMD-induced PF and hepatotoxicity in male Wistar rats. AMD administration resulted in elevated lung contents of hydroxyproline (Hyp), malondialdehyde (MDA), and increased serum levels of transforming growth factor beta-1 (TGF-β1), interferon-γ (IFN-γ), alanine amino transaminase (ALT), aspartate amino transaminase (AST), total cholesterol (TC), and glucose. On the other side, lung content of glutathione reduced (GSH) and serum levels of total anti-oxidant capacity (TAC) were significantly decreased. Histopathologically, AMD caused PF, produced a mild hepatic injury, and increased expression of alpha smooth muscle actin (α-SMA). Treatment with ALA produced a significant reversal of the oxidative stress, fibrosis, and inflammation parameters with reductions in α-SMA expressions, leading to amelioration of histopathological lesions. ALA might provide supportive therapy in AMD-receiving cardiovascular patients.
Keyphrases
- pulmonary fibrosis
- transforming growth factor
- oxidative stress
- age related macular degeneration
- diabetic rats
- drug induced
- smooth muscle
- epithelial mesenchymal transition
- high glucose
- end stage renal disease
- dendritic cells
- poor prognosis
- ejection fraction
- newly diagnosed
- chronic kidney disease
- immune response
- type diabetes
- blood glucose
- heart failure
- cell death
- endothelial cells
- metabolic syndrome
- skeletal muscle
- human health
- insulin resistance
- breast cancer cells
- mesenchymal stem cells
- smoking cessation
- binding protein
- glycemic control
- replacement therapy